429 filings
Page 17 of 22
8-K
yokf9ki48qwvh ow
13 Oct 16
Study Achieves Proof of Concept for CMX157 in HBV Patients with Favorable Therapeutic Profile
12:00am
8-K
be9ipvche0jdu55xl
3 Oct 16
ContraVir to Present at the 15th Annual BIO Investor Forum
12:00am
8-K
aw1ul
29 Sep 16
ContraVir to Receive $1.8 Million Through New Jersey Technology Business Tax Certificate Transfer (NOL) Program
12:00am
8-K
vcyiv
21 Sep 16
ContraVir Pharmaceuticals Appoints Thomas H. Adams, Ph.D., to Board of Directors
12:00am
CT ORDER
ousiirijuq0s0c
15 Sep 16
Confidential treatment order
12:00am
8-K
vos7mbv47uwj9qgoj
22 Aug 16
ContraVir to Release New CRV431 Data Highlighting Potential Synergy with CMX157 Against Hepatitis B
12:00am
8-K/A
5truq7yetgc8bmezw
22 Aug 16
Financial Statements and Exhibits
12:00am
8-K
n7c7 5i9jtjrnr57
9 Aug 16
Other Events
12:00am
8-K
vi26gj426 dpjaougiu
2 Aug 16
ContraVir Reports Positive Data from Phase 1b Study of CMX157
12:00am
8-K
8lpd5nc8
20 Jul 16
ContraVir Pharmaceuticals to Present at 41st Annual International Herpesvirus Workshop
12:00am
8-K
wkuo4rw
18 Jul 16
Appoints Four Renowned Hepatitis B Experts; Carol L. Brosgart, M.D., to Serve as Chair of the Board
12:00am
8-K
egl62i4tdr1k3o5
21 Jun 16
Other Events
12:00am
8-K
xr1ml92w63j cuga8rae
16 Jun 16
ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
12:00am
8-K
2olhxh6tadm
13 Jun 16
ContraVir Completes Merger with Ciclofilin Pharmaceuticals
12:00am
8-K
4knrvp4 hwwiyytk6nq
13 Jun 16
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
7osff1t h80wi7zfucu
1 Jun 16
First Study to Evaluate the Antiviral Power of CMX157 Compared to the Current Standard of Care in Hepatitis B
12:00am
8-K
153 hx7sefo8qtf
31 May 16
ContraVir to Expand Hepatitis B Portfolio through Strategic Merger Agreement with Ciclofilin Pharmaceuticals
12:00am
8-K
c6nxh1 qhkw821
26 May 16
ContraVir Pharmaceuticals to Present at 2016 Marcum MicroCap Conference
12:00am